Sources checked October 23, 2026. The FDA guidance below is an October 15, 2026 archived copy. This page describes product identity and research, not a treatment, dosing or injection recommendation.
What is in the Wolverine peptide stack?
Eppix Labs describes its Wolverine product as a freeze-dried blend of BPC-157 and TB-500, with TB4 shown in parentheses beside TB-500.[1] These are the seller's ingredient labels, not an independent identification of the contents.[1]
The same page describes equal ingredient concentrations and a research-only use restriction.[1] Its commercial name does not identify a particular prescribing clinician, pharmacy or patient-specific preparation.[1]
Treat the blend name as the start of a documentation check. Ask for the exact ingredient identities, preparation, route and lot number rather than assuming that every product using the Wolverine name is interchangeable.
Are TB-500 and thymosin beta-4 the same ingredient?
The exact chemical identity matters.[2] Cayman Chemical's TB-500 acetate sheet identifies its product as the acetylated sequence Ac-LKKTETQ-OH, corresponding to residues 17 through 23 of thymosin beta-4.[2] That sheet identifies a fragment, not the entire parent molecule.[2]
Eppix uses the label TB-500 (TB4), while Cayman's sheet supplies a specific fragment sequence.[1][2] The names alone do not establish that these two products contain the same molecule.[1][2] Match any claimed research to the preparation actually described in the paper.[1][2]
Cayman also distinguishes its product specifications from batch-specific analytical results.[2] A specification sheet is not a certificate for a particular vial.[2]
Has the Wolverine combination been studied in people?
A published knee-pain report included BPC-157 together with thymosin beta-4, but it was a retrospective clinic review rather than a randomized trial of a Wolverine-branded blend.[3] Its original abstract identifies the second ingredient as TB4.[3]
What did the 2021 human knee report measure?
Lee and Padgett reviewed 17 patients and contacted 16 by telephone.[3] Twelve had received BPC-157 alone and four had received BPC-157 with TB4 by knee injection.[3] The authors reported pain improvement in 11 of 12 single-ingredient recipients and three of four combination recipients.[3] Most injections preceded follow-up by six months to one year.[3]
The abstract describes no placebo group or standardized function or quality-of-life instrument.[3] It reports patients' recollections after treatment, not a randomized comparison establishing an added effect of the combination.[3] The reviewed abstract does not identify a Wolverine product or establish equivalence to Cayman's fragment.[3]
What did the 2026 rat combination study measure?
How were the rat groups and outcomes separated?
Bicer and colleagues randomized 32 male rats after surgical Achilles tendon transection and repair to control, BPC-157, TB-500 or both peptides.[4] Each group contained eight rats.[4] Four tendons per group underwent mechanical testing and four underwent tissue assessment.[4] The methods specify intraperitoneal administration and tissue collection on day 30.[4]
For maximum load to failure, the only significant pairwise comparison was TB-500 versus control, with adjusted P = 0.0406.[4] The combination differed significantly from control on total Movin tissue score, P = 0.040, but not on total Bonar score, P = 0.103.[4] It did not differ significantly from the other groups on maximum load.[4] These are endpoint-specific rat observations, not patient outcomes or a human protocol.[4]
Does a research label or compounding claim establish approval?
The Eppix product is labeled for research use.[1] That label describes the seller's intended-use restriction; it is not a prescription or an FDA approval record.[1]
FDA's compounding questions page, as archived October 15, 2026, distinguishes compounded drugs from approved drugs and states that compounded drugs are not FDA-approved.[5] The archive is general guidance, not a decision about a particular Wolverine preparation or the current compounding-list status of either ingredient.[5]
If a clinic describes a preparation as approved or legally compounded, ask for the exact product name, manufacturer or dispensing pharmacy, and the document supporting that statement. Keep those questions separate from whether an individual clinician recommends treatment.
What documentation should you ask a provider to clarify?
Ask which molecule the TB-500 label denotes, whether ingredients are supplied separately or in one blend, and which lot-specific report matches the proposed preparation. A product nickname cannot answer those questions.
Ask whether each cited study used the same ingredients and route.[3][4] The human report involved knee injections, while the rat experiment used intraperitoneal administration after surgery.[3][4] Neither design supplies a self-injection schedule.[3][4]
Request a written explanation of who prescribes, who dispenses and what follow-up the practice offers. This is a documentation checklist, not a recommendation to obtain or use a Wolverine preparation.
Where can you browse related clinic listings?
In Regenerated.com's September 2026 export of 9,042 US clinic records, 2,743 listed Peptide Therapy across 49 states plus Washington, DC. Source: Regenerated.com clinic export, September 2026. This is our directory's category coverage, not market size or a count of Wolverine providers.
Browse Peptide Therapy clinics to compare recorded practices. For local browsing, see Peptide Therapy clinics in Colorado Springs, Colorado and Peptide Therapy clinics in Englewood, Colorado. These category listings do not confirm a particular preparation's availability. A listing is not an endorsement.